ASX:RAC Race Oncology (RAC) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free RAC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume76,322 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Race Oncology alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Race Oncology Stock (ASX:RAC)Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… RAC Stock News HeadlinesMarch 27, 2024 | msn.comRace Oncology achieves ‘major milestone’ in progress of lead drug to human trialsMarch 26, 2024 | au.investing.comRace Oncology key asset RC220 passes milestone with manufactured batch confirmed for human IV useMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 18, 2024 | msn.comJames Ryan in race against time for Leinster Champions Cup tieMarch 18, 2024 | msn.comLeinster star facing race against time to make Champions Cup knock-out tieMarch 17, 2024 | msn.comFulham 3-0 Tottenham: Rodrigo Muniz double deals blow to Spurs in race for Champions LeagueMarch 17, 2024 | au.investing.comRace Oncology appoints Brendan Brown as chief financial officerMarch 13, 2024 | au.investing.comRace Oncology adds international cardiometabolic expert to Scientific Advisory BoardMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 13, 2024 | msn.comInter Miami races to a 2-0 lead in Champions Cup behind goals from Suarez, MessiMarch 13, 2024 | msn.comInternational cardiometabolic expert to join Race Oncology’s scientific advisory boardMarch 12, 2024 | msn.comPaterson CREW honors friend lost to colon cancer with fundraising 5K runMarch 8, 2024 | finance.yahoo.comNo Solution in Sight, Florida Cancer Specialists & Research Institute, Core Ventures Forge Ahead in Race to Recover from Change Healthcare ShutdownMarch 6, 2024 | finance.yahoo.comBiotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningFebruary 28, 2024 | finance.yahoo.comRace Oncology looks to accelerate clinical development of bisantreneFebruary 26, 2024 | msn.comTumor biology may underlie racial differences in certain breast cancer outcomesFebruary 23, 2024 | msn.comNew Duke Study finds breast cancer tumors may differ based on raceFebruary 23, 2024 | msn.comHow did COVID-19 impact cancer incidence trends in the US?February 22, 2024 | msn.comThese ASX biotechs want to tackle cancer head-on for better outcomesFebruary 21, 2024 | msn.comChampions League race: Premier League form table as Man Utd, Spurs and Aston Villa fight for fourth placeFebruary 21, 2024 | msn.com'He makes everybody smile': How Stanley the therapy dog has become De Pere Fire Rescue's pride, joyFebruary 21, 2024 | msn.com‘Significant potential’: This ASX stock is winning the race to make cancer care heart-safeFebruary 19, 2024 | msn.comA Florida doctor ordered radiation therapy for breast cancer. He got the wrong breastFebruary 18, 2024 | msn.comDemocrat Brutally Roasts Marjorie Taylor Greene During House Hearing For ‘Conspiracy Theories and Wild Accusations’February 8, 2024 | msn.comCancer Need Not Be End Of World: Doctor Shares Dos And Don'ts Of Living With Cancer, Importance Of ExerciseFebruary 4, 2024 | msn.comAfter a mini-stroke, Sarasota surgical tech started walking; now she runs marathonsFebruary 4, 2024 | msn.comSupreme Court won’t block West Point from considering race in admissionsSee More Headlines Receive RAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RAC CUSIPN/A CIKN/A Webwww.raceoncology.com Phone61 3 9097 1656FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,170,000.00 Net Margins-192.15% Pretax MarginN/A Return on Equity-43.67% Return on Assets-28.46% Debt Debt-to-Equity RatioN/A Current Ratio28.36 Quick Ratio23.71 Sales & Book Value Annual Sales$5.82 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.29 Book ValueA$0.12 per share Price / BookN/AMiscellaneous Outstanding Shares164,780,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.37 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Daniel TillettChief Executive OfficerDr. Peter M. Smith Ph.D. (Age 61)Executive Director Comp: $635Ms. Christina ManfreChief Financial OfficerProf. Tim HammondInterim Chief Scientific OfficerDr. Michelle RashfordChief Medical OfficerMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPhillip(Phil) LynchSold 21,457 sharesTotal: $18,989.45 ($0.89/share)Peter (Pete) SmithSold 440,019 sharesTotal: $374,016.15 ($0.85/share) RAC Stock Analysis - Frequently Asked Questions How were Race Oncology's earnings last quarter? Race Oncology Limited (ASX:RAC) posted its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.03) earnings per share (EPS) for the quarter. Race Oncology had a negative trailing twelve-month return on equity of 43.67% and a negative net margin of 192.15%. What other stocks do shareholders of Race Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX). This page (ASX:RAC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Race Oncology Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.